ArticleInfection and immunity2008
Immunogenicity and protective efficacy of recombinant Campylobacter jejuni flagellum-secreted proteins in mice.
Article in Infection and immunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Campylobacter jejuni: targeting host cells, adhesion, invasion, and survival.Applied microbiology and biotechnology · 2023Review
- The Missing Pieces: The Role of Secretion Systems inBiomolecules · 2023Review
- Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022Review
- Multi-Omics Approach Reveals the Potential Core Vaccine Targets for the Emerging Foodborne PathogenFrontiers in microbiology · 2021Article
- An Updated Classification System and Review of the Lipooligosaccharide Biosynthesis Gene Locus inFrontiers in microbiology · 2020Review
- In vitro spleen cell cytokine responses of adult mice immunized with a recombinant PorA (major outer membrane protein [MOMP]) from Campylobacter jejuni.Scientific reports · 2019Article
- A proteome-wide screen of Campylobacter jejuni using protein microarrays identifies novel and conformational antigens.PloS one · 2019Article
- Article
- Article
- Article
- Induction of cytokines in different organs after intranasal inoculation of Campylobacter jejuni in mice.Gut pathogens · 2012Article
- Microarray-based method for screening of immunogenic proteins from bacteria.Journal of nanobiotechnology · 2012Article
- Distribution of flagella secreted protein and integral membrane protein among Campylobacter jejuni isolated from Thailand.Gut pathogens · 2011Article
- Recombinant PorA, the major outer membrane protein of Campylobacter jejuni, provides heterologous protection in an adult mouse intestinal colonization model.Clinical and vaccine immunology : CVI · 2010Article
- Association of Campylobacter jejuni Cj0859c gene (fspA) variants with different C. jejuni multilocus sequence types.Applied and environmental microbiology · 2010Article
- Advances in Campylobacter biology and implications for biotechnological applications.Microbial biotechnology · 2010Review
- Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.Infection and immunity · 2010Article
- Immune response to and histopathology of Campylobacter jejuni infection in ferrets (Mustela putorius furo).Comparative medicine · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunogenicity and protective efficacy of three Campylobacter jejuni flagellum-secreted proteins, FlaC, FspA1, and FspA2, were compared by use of a mouse model. Mice were immunized intranasally with each protein with or without LTR192G as the adjuvant and challenged intranasally with C. jejuni 81-176 or CG8486. All three proteins were immunogenic, although FspA1 induced the highest levels of serum immunoglobulin G (IgG) and fecal IgA. Although immunogenic, FlaC provided only 18% protection against disease from C. jejuni 81-176. Immunization with FspA1 resulted in 57.8% protection without adjuvant or 63.8% protection with adjuvant against homologous challenge with 81-176. Alternatively, immunization with FspA2 provided 38.4% (without adjuvant) or 47.2% (with adjuvant) protection against disease from homologous challenge with CG8486. In contrast to FspA2, FspA1 provided some heterologous protection against C. jejuni CG8486 when delivered with (31.2%) or without (44.8%) LTR192G. These results suggest that FspA1 may be a good subunit vaccine candidate against C. jejuni disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.